<i>Pseudomonas</i>Exotoxin A‐Based Immunotoxins for Targeted Cancer Therapy

Wolf, Philipp; Elsässer‐Beile, Ursula

doi:10.1002/9780470626528.ch12

Cited by 5 publications

(1 citation statement)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exotoxin A-immunotoxins, such as that produced by P. aeruginosa, kill cancer cells by binding specifically to overexpressed cell surface receptors, which carries them into the cell, where they catalyze the ADP-ribosylation of the eukaryotic elongation factor 2 (eEF-2) in host cells, ultimately affecting protein synthesis and inducing programmed cell death. Clinical trials with different exotoxin A-immunotoxins have demonstrated that such bacterial products present better results in eliminating cells derived from hematological malignancies over those originated from solid tumors (Wolf & Elsasser-Beile, 2009;Bernardes et al, 2010). P. aeruginosa has also been demonstrated to produce another immunoglobulin-like product named azurin, a water soluble enzyme involved in the electron transport chain.…”

Section: The Microbial World Of Anticancer Drugsmentioning

confidence: 99%

Biological Diversity and Sustainable Resources Use

Grillo¹,

Venora²

2011

View full text Add to dashboard Cite

Dr. Oscar Grillo was born in Catania (Sicily) in 1977, he is a food technologist with an international PhD in applied and environmental botany. Since 2003 he has been working as researcher at the Stazione Sperimentale di Granicoltura per la Sicilia, a governmental institute of agronomic research, mainly working with computer vision applied to food matrices and plant structures, above all seeds, and in particular studying wheat and the related leguminous. Currently, he is working also at the Sardinian Germplasm Bank of the Biodiversity Conservation Centre of the University of Cagliari on projects devoted to seed characterization and identification by image analysis. Results of his work have been published in many peer-reviewed journals papers and international conference papers. Referee for a few peer-reviewed journals, many times he has been invited as teacher/lecturer/speaker by some universities and research centres in Spain and Italy. He has trained many MSc and PhD students, who have made their own contributions to the agronomical and botanical research.Dr. Gianfranco Venora is a biologist, born in Caltagirone (Sicily) in 1958, where he lives and works. He took his University degree in 1981, and since 1982 he has been working as researcher at the Stazione Sperimentale di Granicoltura per la Sicilia. His working expertise is mainly about durum wheat and leguminous breeding. At the beginning of 1990, after some years of experience on karyotyping cropped and wild species of agronomical importance, he was fascinated by computer vision applied to food matrices and plant anatomical structures, studying wheat and the related leguminous. He was recently nominated as professor to the research doctorate on Applied and Environmental Botany of the University of Cagliari. Many peer-reviewed journals published his papers and he was invited as speaker in many international conferences, and as teacher/lecturer by some universities and research centres in Germany, Netherlands, Bulgaria, Spain, Czech Republic and Italy. Gianfranco Venora is currently referee for about 15 peer-reviewed journals and tutor of many MSc and PhD students.

show abstract

Section: The Microbial World Of Anticancer Drugsmentioning

confidence: 99%

Biological Diversity and Sustainable Resources Use

Grillo¹,

Venora²

2011

View full text Add to dashboard Cite

show abstract

Engineering of bacterial strains and their products for cancer therapy

Bernardes

Chakrabarty

Fialho

2013

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

The use of live bacteria in cancer therapies offers exciting possibilities. Nowadays, an increasing number of genetically engineered bacteria are emerging in the field, with applications both in therapy and diagnosis. In parallel, purified bacterial products are also gaining relevance as new classes of bioactive products to treat and prevent cancer growth and metastasis. In the first part of the article, we review the latest findings regarding the use of live bacteria and products as anti-cancer agents, paying special attention to immunotoxins, proteins, and peptides. In particular, we focus on the recent results of using azurin or its derived peptide as anticancer therapeutic agents. In the second part, we discuss the challenges of using metagenomic techniques as a distinctive approach for discovering new anti-cancer agents from bacterial origin.

show abstract